Insulet (NASDAQ:PODD) Rating Lowered to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Insulet to “Hold” from “Buy,” joining a broader wave of analyst caution. The consensus rating is now “Hold,” with 13 Buy, 12 Hold and 1 Sell ratings, and an average price target of $186.68.
• Several firms sharply reduced their price targets, including Stifel Nicolaus to $180, JPMorgan to $152, Wells Fargo to $144 and Leerink Partners to $145, though Stifel maintained a Buy rating.
• Insulet reported a quarterly earnings beat, posting $1.66 in EPS versus the $1.47 consensus and $801.7 million in revenue versus $787.39 million expected. Revenue rose 23.5% year over year, while the stock opened at $149.01 and recently traded near its 12-month low.

Insulet (NASDAQ:PODD - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Saturday, Wall Street Zen reports.

Several other equities research analysts also recently commented on PODD. Stifel Nicolaus reduced their target price on shares of Insulet from $225.00 to $180.00 and set a "buy" rating on the stock in a research note on Thursday, August 6th. Leerink Partners downgraded Insulet from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $247.00 to $145.00 in a report on Thursday, August 6th. JPMorgan Chase & Co. reiterated a "neutral" rating and set a $152.00 target price (down from $275.00) on shares of Insulet in a research note on Thursday, August 6th. Wells Fargo & Company downgraded Insulet from an "overweight" rating to an "equal weight" rating and cut their target price for the company from $255.00 to $144.00 in a research report on Wednesday, August 5th. Finally, Oppenheimer cut Insulet from an "outperform" rating to a "market perform" rating in a research note on Wednesday, August 5th. Thirteen equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $186.68.

Insulet Trading Up 0.6%

Shares of Insulet stock opened at $149.01 on Friday. The stock has a market cap of $10.33 billion, a PE ratio of 27.85, a price-to-earnings-growth ratio of 1.17 and a beta of 1.11. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. Insulet has a 12-month low of $126.40 and a 12-month high of $354.88. The company has a 50-day moving average of $140.58 and a two-hundred day moving average of $154.66.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.19. The business had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The business's quarterly revenue was up 23.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, research analysts anticipate that Insulet will post 6.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Insulet

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in shares of Insulet in the 2nd quarter worth about $1,018,582,000. Arrowstreet Capital Limited Partnership grew its holdings in Insulet by 462.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier's stock worth $258,088,000 after purchasing an additional 1,011,369 shares during the period. Man Group plc bought a new position in shares of Insulet during the second quarter valued at $78,746,000. Amundi lifted its position in Insulet by 13.6% in the 2nd quarter. Amundi now owns 507,847 shares of the medical instruments supplier's stock valued at $77,320,000 after acquiring an additional 60,929 shares in the last quarter. Finally, Bank of America Corp DE bought a new position in Insulet during the second quarter valued at approximately $64,921,000.

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company's primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.